Powered by: Motilal Oswal

News

Natco Pharma gains on making strategic investment in ISCA Inc Natco Pharma is currently trading at Rs. 911.00, up by 6.60 points or 0.73% from its previous closing of Rs. 904.40 on the BSE. The scrip opened at Rs. 918.35 and has touched a high and low of Rs. 918.35 and Rs. 899.90 respectively. So far 9278 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 920.00 on 10-Aug-2023 and a 52 week low of Rs. 502.00 on 02-Feb-2023. Last one week high and low of the scrip stood at Rs....
Natco Pharma gains on making strategic investment in ISCA Inc
Natco Pharma gains on making strategic investment in ISCA Inc
Source: Accord Fintech
31/08/2023 11:38:42 AM
Natco Pharma soars after filing ANDA for generic version of Erdafitinib Tablets Natco Pharma is currently trading at Rs. 794.65, up by 14.75 points or 1.89% from its previous closing of Rs. 779.90 on the BSE. The scrip opened at Rs. 780.05 and has touched a high and low of Rs. 797.90 and Rs. 773.70 respectively. So far 46549 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 797.90 on 26-Jul-2023 and a 52 week low of Rs. 502.00 on 02-Feb-2023. Last one week high and low of the scrip stood at R...
Natco Pharma soars after filing ANDA for generic version of Erdafitinib Tablets
Natco Pharma soars after filing ANDA for generic version of Erdafitinib Tablets
Source: Accord Fintech
26/07/2023 3:02:37 PM
Small Cap : Buy Natco Pharma Ltd For Target Rs. 765- Geojit Financial Services Export formulations boosted revenue NATCO Pharma Ltd. (NATCO) is an India-based vertically integrated and R&D focused enterprise, engaged in developing, manufacturing and marketing finished dosage formulations and active pharmaceutical ingredients and intermediates. • FY23 revenue increased 39% YoY to Rs. 2,707 cr, owing to robust sales growth in the US, Canada, and Brazil. • EBITDA grew 255% YoY to Rs. 935cr, led by a strong contribution from export formulations. EBITD...
Small Cap : Buy Natco Pharma Ltd For Target Rs. 765- Geojit Financial Services
Small Cap : Buy Natco Pharma Ltd For Target Rs. 765- Geojit Financial Services
Source: Geojit Financial Services Ltd
22/06/2023 3:33:03 PM
Natco Pharma zooms on getting nod to incorporate subsidiary company in Indonesia Natco Pharma is currently trading at Rs. 570.70, up by 16.95 points or 3.06% from its previous closing of Rs. 553.75 on the BSE. The scrip opened at Rs. 567.95 and has touched a high and low of Rs. 575.70 and Rs. 555.85 respectively. So far 6165 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 803.00 on 29-Apr-2022 and a 52 week low of Rs. 502.00 on 02-Feb-2023. Last one week high and low of the scrip stood at Rs...
Natco Pharma zooms on getting nod to incorporate subsidiary company in Indonesia
Natco Pharma zooms on getting nod to incorporate subsidiary company in Indonesia
Source: Accord Fintech
21/04/2023 3:49:02 PM
Natco Pharma gains on launching additional strengths for generic version of Revlimid in USA Natco Pharma is currently trading at Rs. 564.70, up by 4.45 points or 0.79% from its previous closing of Rs. 560.25 on the BSE. The scrip opened at Rs. 568.35 and has touched a high and low of Rs. 568.40 and Rs. 559.55 respectively. So far 586 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 872.60 on 10-Mar-2022 and a 52 week low of Rs. 502.00 on 02-Feb-2023. Last one week high and low of the scrip stood at Rs. ...
Natco Pharma gains on launching additional strengths for generic version of Revlimid in USA
Natco Pharma gains on launching additional strengths for generic version of Revlimid in USA
Source: Accord Fintech
10/03/2023 9:53:02 AM
Natco Pharma gains on launching Pomalidomide Capsules in Canada Natco Pharma is currently trading at Rs. 541.15, up by 3.05 points or 0.57% from its previous closing of Rs. 538.10 on the BSE. The scrip opened at Rs. 548.25 and has touched a high and low of Rs. 548.25 and Rs. 538.90 respectively. So far 709 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 920.00 on 08-Mar-2022 and a 52 week low of Rs. 502.00 on 02-Feb-2023. Last one week high and low of the scrip stood at Rs. ...
Natco Pharma gains on launching Pomalidomide Capsules in Canada
Natco Pharma gains on launching Pomalidomide Capsules in Canada
Source: Accord Fintech
1/03/2023 10:34:58 AM
Small Cap : Buy Natco Pharma Ltd For Target Rs. 704 - Geojit Financial Services Muted revenue growth; agro-chem to aid earnings NATCO Pharma (NATCO) is an India-based vertically integrated and R&D focused enterprise, engaged in developing, manufacturing and marketing finished dosage formulations and active pharmaceutical ingredients and intermediates * Natco witnessed 67% revenue growth in H1FY23, owing to robust Revlimid sales. * EBITDA margins expanded 1436bps to 37% in H1FY23 from 23% in H1FY22 led by strong contribution from export formulations. &bull...
Small Cap : Buy Natco Pharma Ltd For Target Rs. 704 - Geojit Financial Services
Small Cap : Buy Natco Pharma Ltd For Target Rs. 704 - Geojit Financial Services
Source: Geojit Financial Services Ltd
5/12/2022 4:16:01 PM
Natco Pharma gains on launching first generic version of Pomalyst Capsules in Australian market Natco Pharma is currently trading at Rs. 617.00, up by 3.80 points or 0.62% from its previous closing of Rs. 613.20 on the BSE. The scrip opened at Rs. 609.05 and has touched a high and low of Rs. 617.35 and Rs. 609.05 respectively. So far 1317 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 942.15 on 17-Jan-2022 and a 52 week low of Rs. 582.75 on 21-Oct-2022. Last one week high and low of the scrip stood at Rs....
Natco Pharma gains on launching first generic version of Pomalyst Capsules in Australian market
Natco Pharma gains on launching first generic version of Pomalyst Capsules in Australian market
Source: Accord Fintech
10/11/2022 11:14:32 AM
Natco Pharma gains on launching Chlorantraniliprole combination Agro Products in India Natco Pharma is currently trading at Rs. 618.05, up by 5.55 points or 0.91% from its previous closing of Rs. 612.50 on the BSE. The scrip opened at Rs. 617.95 and has touched a high and low of Rs. 621.85 and Rs. 613.60 respectively. So far 16490 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 942.15 on 17-Jan-2022 and a 52 week low of Rs. 593.20 on 28-Sep-2022. Last one week high and low of the scrip stood at Rs...
Natco Pharma gains on launching Chlorantraniliprole combination Agro Products in India
Natco Pharma gains on launching Chlorantraniliprole combination Agro Products in India
Source: Accord Fintech
4/10/2022 12:13:44 PM
Natco Pharma surges on getting CTPR launch approval from Delhi High Court Natco Pharma is currently trading at Rs. 652.85, up by 15.45 points or 2.42% from its previous closing of Rs. 637.40 on the BSE. The scrip opened at Rs. 653.00 and has touched a high and low of Rs. 660.00 and Rs. 648.95 respectively. So far 36703 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 942.15 on 17-Jan-2022 and a 52 week low of Rs. 600.10 on 12-Sep-2022. Last one week high and low of the scrip stood at R...
Natco Pharma surges on getting CTPR launch approval from Delhi High Court
Natco Pharma surges on getting CTPR launch approval from Delhi High Court
Source: Accord Fintech
20/09/2022 10:58:31 AM
Natco Pharma rises on getting nod to sell stake in Nativita Natco Pharma is currently trading at Rs. 615.05, up by 5.85 points or 0.96% from its previous closing of Rs. 609.20 on the BSE. The scrip opened at Rs. 615.00 and has touched a high and low of Rs. 620.10 and Rs. 612.00 respectively. So far 22145 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 993.45 on 06-Sep-2021 and a 52 week low of Rs. 607.00 on 02-Sep-2022. Last one week high and low of the scrip stood at Rs...
Natco Pharma rises on getting nod to sell stake in Nativita
Natco Pharma rises on getting nod to sell stake in Nativita
Source: Accord Fintech
5/09/2022 11:43:59 AM
Natco Pharma rises on getting USFDA`s tentative approval for Trabectedin for Injection Natco Pharma is currently trading at Rs. 659.70, up by 8.40 points or 1.29% from its previous closing of Rs. 651.30 on the BSE. The scrip opened at Rs. 663.95 and has touched a high and low of Rs. 669.00 and Rs. 657.50 respectively. So far 9139 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 993.45 on 06-Sep-2021 and a 52 week low of Rs. 607.95 on 31-May-2022. Last one week high and low of the scrip stood at Rs....
Natco Pharma rises on getting USFDA`s tentative approval for Trabectedin for Injection
Natco Pharma rises on getting USFDA`s tentative approval for Trabectedin for Injection
Source: Accord Fintech
18/08/2022 10:20:46 AM
Natco Pharma rises on getting approval for its partner`s ANDA for Cabazitaxel Intravenous Solution Natco Pharma is currently trading at Rs. 665.00, up by 3.80 points or 0.57% from its previous closing of Rs. 661.20 on the BSE. The scrip opened at Rs. 652.50 and has touched a high and low of Rs. 677.30 and Rs. 652.50 respectively. So far 4752 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1092.00 on 26-Jul-2021 and a 52 week low of Rs. 607.95 on 31-May-2022. Last one week high and low of the scrip stood at Rs...
Natco Pharma rises on getting approval for its partner`s ANDA for Cabazitaxel Intravenous Solution
Natco Pharma rises on getting approval for its partner`s ANDA for Cabazitaxel Intravenous Solution
Source: Accord Fintech
26/07/2022 10:19:32 AM
Hold Natco Pharma Ltd For Target Rs.820 - ICICI Direct gRevlimid bumps exports; traction in near term… About the stock: Natco has, over the years, developed a knack for manufacturing complex generic products with few competitors, especially for the US market. * India formulations mainly comprise oncology products (38 brands). For the US, it follows partnership products for risky launches and acquired Dash Pharma for front-end presence. It has six FDF, two API manufacturing facilities and two crop health sciences units * Maiden ent...
Hold Natco Pharma Ltd For Target Rs.820 - ICICI Direct
Hold Natco Pharma Ltd For Target Rs.820 - ICICI Direct
Source: ICICI Direct
4/06/2022 10:56:07 AM
Natco Pharma surges on launching first generic version of Nexavar Tablets in US market Natco Pharma is currently trading at Rs. 713.95, up by 21.90 points or 3.16% from its previous closing of Rs. 692.05 on the BSE. The scrip opened at Rs. 699.80 and has touched a high and low of Rs. 729.95 and Rs. 686.05 respectively. So far 12738 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1188.05 on 06-Jul-2021 and a 52 week low of Rs. 607.95 on 31-May-2022. Last one week high and low of the scrip stood at ...
Natco Pharma surges on launching first generic version of Nexavar Tablets in US market
Natco Pharma surges on launching first generic version of Nexavar Tablets in US market
Source: Accord Fintech
1/06/2022 10:48:24 AM
Natco Pharma posts Q4 net loss of Rs 61.30 cr The company reported standalone net loss during the quarter stood at Rs 61.30 crore compared to net profit of Rs 57.20 crore in the previous year quarter.  Net revenue of the company rose substantially by 65.04 per cent at Rs 514.10 crore in January-March quarter of this fiscal as against Rs 311.50 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 134.71 per cent to Rs 551.80 crore from Rs 235.10 crore in year ago period. Other Inc...
Natco Pharma posts Q4 net loss of Rs 61.30 cr
Natco Pharma posts Q4 net loss of Rs 61.30 cr
Source: Dion Global Solutions Ltd
31/05/2022 9:01:21 AM
Natco Pharma, Thejo Engineering winners of Moneylife Foundation's 1st Corporate Governance Award  Hyderabad-based Natco Pharma Ltd and Chennai-based Thejo Engineering Ltd are the winner and runner-up, respectively, of Moneylife Foundation's inaugural Corporate Governance Award. In an online function, M. Damodaran, former Chairman of SEBI, announced the winner and runner-up from five shortlisted nominees. The five finalists for this year's award were KPR Mill Ltd, Laurus Labs Ltd, Natco Pharma, Suven Pharma Ltd and Thejo Engineering. Congratulating all the shortlisted c...
Natco Pharma, Thejo Engineering winners of Moneylife Foundation's 1st Corporate Governance Award
Natco Pharma, Thejo Engineering winners of Moneylife Foundation's 1st Corporate Governance Award
Source: IANS
7/01/2022 9:22:40 AM
Natco Pharma gains after its arm completes acquisition of Dash Pharmaceuticals Natco Pharma is currently trading at Rs. 909.70, up by 5.70 points or 0.63% from its previous closing of Rs. 904.00 on the BSE. The scrip opened at Rs. 904.65 and has touched a high and low of Rs. 911.95 and Rs. 904.65 respectively. So far 4284 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1188.95 on 24-May-2021 and a 52 week low of Rs. 771.00 on 19-Feb-2021. Last one week high and low of the scrip stood at Rs...
Natco Pharma gains after its arm completes acquisition of Dash Pharmaceuticals
Natco Pharma gains after its arm completes acquisition of Dash Pharmaceuticals
Source: Accord Fintech
3/01/2022 12:00:42 PM
Natco Pharma gains on getting nod for Molnupiravir Capsules for Covid-19 treatment in India Natco Pharma gains on getting nod for Molnupiravir Capsules for Covid-19 treatment in India Dec-29-2021   11:20 Hrs IST Natco Pharma is currently trading at Rs. 899.10, up by 8.65 points or 0.97% from its previous closing of Rs. 890.45 on the BSE. The scrip opened at Rs. 900.00 and has touched a high and low of Rs. 910.00 and Rs. 895.30 respectively. So far 12163 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week ...
Natco Pharma gains on getting nod for Molnupiravir Capsules for Covid-19 treatment in India
Natco Pharma gains on getting nod for Molnupiravir Capsules for Covid-19 treatment in India
Source: Accord Fintech
29/12/2021 11:42:39 AM
Hold Natco Pharma Ltd For Target Rs.1040 - ICICI Direct Sequential domestic recovery amid Covid sales… About the stock: Natco is engaged in developing, manufacturing and marketing complex products in niche therapeutic areas. * Products comprise FDFs, sold in India, US & RoW market as well as APIs, used for captive consumption & customers from international markets * It has six FDF and two APIs manufacturing facilities to aid 50+ products in domestic FDF, 39 DMFs in APIs and 30+ products in International FDF with 27%, 18% &a...
Hold Natco Pharma Ltd For Target Rs.1040 - ICICI Direct
Hold Natco Pharma Ltd For Target Rs.1040 - ICICI Direct
Source: ICICI Direct
15/10/2021 11:26:54 AM
Hold Natco Pharma Ltd For Target Rs.1,030 - ICICI Securities Weak quarter; India business recovers Natco Pharma’s (Natco) Q1FY22 performance was below estimates with a miss in exports and API revenues. However, India business recovered well with recovery in oncology business and upside from covid-19 related portfolio. Revenue declined 27.2% to Rs4.1bn while adjusted PAT dropped 38.9% to Rs750mn (I-Sec: Rs928mn). EBITDA margin was also down 360bps YoY to 26.8% due to lower revenue. Continued pressure on domestic oncology segment, though reco...
Hold Natco Pharma Ltd For Target Rs.1,030 - ICICI Securities
Hold Natco Pharma Ltd For Target Rs.1,030 - ICICI Securities
Source: ICICI Securities
6/10/2021 11:57:45 AM
Natco Pharma soars as its arm launches NAT-LENALIDOMIDE Capsules Natco Pharma is currently trading at Rs. 975.70, up by 35.10 points or 3.73% from its previous closing of Rs. 940.60 on the BSE. The scrip opened at Rs. 950.00 and has touched a high and low of Rs. 981.95 and Rs. 950.00 respectively. So far 6505 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1188.95 on 24-May-2021 and a 52 week low of Rs. 732.00 on 09-Sep-2020. Last one week high and low of the scrip stood at R...
Natco Pharma soars as its arm launches NAT-LENALIDOMIDE Capsules
Natco Pharma soars as its arm launches NAT-LENALIDOMIDE Capsules
Source: Accord Fintech
2/09/2021 12:23:10 PM
Hold Natco Pharma Ltd For Target Rs. 1,109 - ICICI Securities Weak quarter; set for strong FY22 Natco Pharma’s (Natco) Q4FY21 performance was much lower than estimates with a miss in India and US revenues. Additionally, weak flu season impacted sales from Tamiflu. Revenue declined 27.2% to Rs3.3bn while adjusted PAT dropped 43.7% to Rs530mn (I-Sec: Rs1.0bn). EBITDA margin was also down 520bps YoY to 23.0% due to low revenue. Continued pressure on domestic oncology segment and negligible Tamiflu sales in US were key reasons for weak quarter. How...
Hold Natco Pharma Ltd For Target Rs. 1,109 - ICICI Securities
Hold Natco Pharma Ltd For Target Rs. 1,109 - ICICI Securities
Source: ICICI Securities
15/07/2021 10:57:59 AM
Hold Natco Pharma Ltd For Target Rs. 1,010 - ICICI Direct Covid drags FY21; new launches to drive FY22… Natco’s Q4FY21 revenues de-grew 27.2% YoY to | 331.3 crore due to decline across verticals. Export formulations declined 27.6% YoY to | 158.8 crore due to significant drop in gTamiflu sales. Domestic formulations degrew 20.3% to | 81.8 crore amid a sharp fall in oncology sales. API business declined 26.6% YoY | 70.8 crore. EBITDA margins contracted 521 bps YoY to 23%, mainly due to higher employee cost. EBITDA fell 40.6% YoY to | 7...
Hold Natco Pharma Ltd For Target Rs. 1,010 - ICICI Direct
Hold Natco Pharma Ltd For Target Rs. 1,010 - ICICI Direct
Source: ICICI Direct
8/07/2021 9:58:46 AM
Natco Pharma Limited that the company received the approval from USFDA for REVLIMID By Mr. Yash Gupta, Angel Broking Ltd Below are Quote on Natco Pharma Limited that the company received the approval from USFDA for REVLIMID by Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd  Natco Pharma Limited that the company received the approval from USFDA for REVLIMID. Natco Pharma Limited announced that the company has received the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, 5mg, 1 Omg, 15mg, and 25mg strengths, from the U...
Natco Pharma Limited that the company received the approval from USFDA for REVLIMID By Mr. Yash Gupta, Angel Broking Ltd
Natco Pharma Limited that the company received the approval from USFDA for REVLIMID By Mr. Yash Gupta, Angel Broking Ltd
Source: Angel Broking Ltd
24/05/2021 12:22:42 PM
Natco Pharma zooms on starting Phase-III Clinical Trial of Molnupiravir capsules for Covid-19 treatment Natco Pharma is currently trading at Rs. 1105.00, up by 114.20 points or 11.53% from its previous closing of Rs. 990.80 on the BSE. The scrip opened at Rs. 1188.95 and has touched a high and low of Rs. 1188.95 and Rs. 1100.00 respectively. So far 109062 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,188.95 on 24-May-2021 and a 52 week low of Rs. 573.30 on 28-May-2020. Last one week high and low of the scrip s...
Natco Pharma zooms on starting Phase-III Clinical Trial of Molnupiravir capsules for Covid-19 treatment
Natco Pharma zooms on starting Phase-III Clinical Trial of Molnupiravir capsules for Covid-19 treatment
Source: Accord Fintech
24/05/2021 10:32:14 AM
Natco Pharma gains on signing voluntary licensing agreement with Lilly for Baricitinib for Covid-19 in India Natco Pharma is currently trading at Rs. 925.55, up by 5.00 points or 0.54% from its previous closing of Rs. 920.55 on the BSE. The scrip opened at Rs. 923.00 and has touched a high and low of Rs. 928.75 and Rs. 923.00 respectively. So far 2212 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 995.05 on 28-Sep-2020 and a 52 week low of Rs. 573.30 on 28-May-2020. Last one week high and low of the scrip stood at Rs....
Natco Pharma gains on signing voluntary licensing agreement with Lilly for Baricitinib for Covid-19 in India
Natco Pharma gains on signing voluntary licensing agreement with Lilly for Baricitinib for Covid-19 in India
Source: Accord Fintech
18/05/2021 10:11:36 AM
Natco Pharma Ltd signs VLA for manufacture of Baricitinib By Mr. Yash Gupta, Angel Broking Ltd Below are Quote on NATCO signs VLA for manufacture of Baricitinib by Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd    NATCO signs Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India Natco Pharma Limited announced the signing of a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company, for the manufacture and commercialization of the drug Baricitinib for Covid-19 indication in...
Natco Pharma Ltd signs VLA for manufacture of Baricitinib By Mr. Yash Gupta, Angel Broking Ltd
Natco Pharma Ltd signs VLA for manufacture of Baricitinib By Mr. Yash Gupta, Angel Broking Ltd
Source: Angel Broking Ltd
18/05/2021 8:52:59 AM
MTF Stock Pick - Buy  Natco Pharma Ltd For Target Rs. 1170 - HDFC Securities MTF Stock Pick  Buy Natco Pharma Ltd For Target Rs. 1170 - HDFC Securities  Stock price has broken out from bullish “Pennant” pattern on the daily charts Rising volumes during the breakout has validated the upside breakout Stock has been trading above important moving average parameters, indicating uptrend on all time frames Pharma Sector has been one of the best performing sector and still holding it s strength Stock price has bro...
MTF Stock Pick - Buy  Natco Pharma Ltd For Target Rs. 1170 - HDFC Securities
MTF Stock Pick - Buy  Natco Pharma Ltd For Target Rs. 1170 - HDFC Securities
Source: HDFC Securities Ltd
4/05/2021 12:29:45 PM
Natco Pharma received Emergency Use approval By Mr. Yash Gupta, Angel Broking Ltd Below are Quote on Natco Pharma received Emergency Use approval by Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd    Natco Pharma Limited has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients. Natco will be requesting a Compulsory License based...
Natco Pharma received Emergency Use approval By Mr. Yash Gupta, Angel Broking Ltd
Natco Pharma received Emergency Use approval By Mr. Yash Gupta, Angel Broking Ltd
Source: Angel Broking Ltd
3/05/2021 2:14:49 PM
Natco Pharma jumps on getting emergency use approval for Baricitinib tablets for Covid-19 treatment Natco Pharma is currently trading at Rs. 918.10, up by 21.45 points or 2.39% from its previous closing of Rs. 896.65 on the BSE. The scrip opened at Rs. 920.00 and has touched a high and low of Rs. 935.00 and Rs. 915.30 respectively. So far 14078 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 995.05 on 28-Sep-2020 and a 52 week low of Rs. 556.50 on 15-May-2020. Last one week high and low of the scrip stood at R...
Natco Pharma jumps on getting emergency use approval for Baricitinib tablets for Covid-19 treatment
Natco Pharma jumps on getting emergency use approval for Baricitinib tablets for Covid-19 treatment
Source: Accord Fintech
3/05/2021 9:51:09 AM
Natco Pharma rises on launching Brivaracetam tablets in India Natco Pharma is currently trading at Rs. 807.05, up by 4.85 points or 0.60% from its previous closing of Rs. 802.20 on the BSE. The scrip opened at Rs. 815.00 and has touched a high and low of Rs. 817.90 and Rs. 795.10 respectively. So far 5037 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 995.05 on 28-Sep-2020 and a 52 week low of Rs. 450.00 on 25-Mar-2020. Last one week high and low of the scrip stood at Rs....
Natco Pharma rises on launching Brivaracetam tablets in India
Natco Pharma rises on launching Brivaracetam tablets in India
Source: Accord Fintech
26/02/2021 12:20:24 PM